Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Summary

This phase I/II trial studies the side effects and best dose of lenalidomide and how well it works in treating older patients with acute myeloid leukemia (AML) who have undergone stem cell transplant. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.

Timeline

Start

2013-12

Primary completion

2015-01

Completion

2016-01

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

Indications